Westudied the effects of deoxyspergualin (NKT-01)on the events of lymphocyte activation in vivo by inoculating mice in the footpad with allogeneic spleen cells, and compared the effects with those of cyclosporin A (CyA). The administration of NKT-01increased the numbers of cells recovered from the popliteal lymph node (PLN) 7 days after inoculation, but inhibited the proliferation of these cells in the presence of exogenous interleukin 2 (IL-2). NKT-01enhanced IL-2 production, but suppressed the production of macrophage activating factor (MAF) in the mixed lymphocyte reaction between the PLN cells and allogeneic spleen cells treated with mitomycin C. CyA decreased the numbers of PLN cells little, and suppressed the response to exogenous IL-2 and the production of both IL-2 and MAF. Results with tumor cells used as allogeneic cells suggested that there was a close relationship between the suppression of MAFproduction by NKT-01 and its inhibition of allograft rejection. The findings showed that NKT-01 inhibited both the MAFproduction by and the response to IL-2 of PLNcells, and that these effects were involved in the suppression of allograft rejection by NKT-01. 1 675 NKT-011'^is a derivative of the antitumor antibiotic spergualin3). It is a potent immunosuppressive drug that suppresses both antibody formation and delayed-type hypersensitivity4), prolongs allograft survival in several transplantation systems*0 , and prevents the appearance of autoimmunediseases in mixed lymphocyte reaction (MLR)/MpJ-lpr/lpr and [NZB x NZW]Fxmice6>7). The immunosuppressive mechanism of NKT-01 is not known. The production of interleukin 2 (IL-2) and IL-3 is enhanced by NKT-01 in some experimental systems8>9). Here, we studied the effects of NKT-01 on some of the immunological properties of cells from popliteal lymph node (PLN) in mice inoculated in the footpad with allogeneic cells, and compared the effects with those of cyclosporin A (CyA).
Materials and Methods

Animals
Female C57BL/6 mice were purchased from the Shizuoka Agricultural Cooperative Association for Laboratory Animals, Japan. Female BALB/c mice were purchased from Charles River Japan Inc. All mice used in the experiments were 6 to 8 weeks of age.
Drugs
NKT-01 was prepared by Takara Shuzo Co., Ltd.2). CyA (Sandimmun) was purchased from the Sankyo Co., Ltd. NOV. 1988 Transplantation of Allogeneic Spleen Cells C57BL/6 (H-2b) mice were inoculated in the footpad with 107 spleen cells from BALB/c(H-2d) mice. NKT-01 or CyA was injected intraperitoneally for 6 days at daily doses of 3.13 or 20 mg/kg, respectively, starting the day after the transplantation.
Cell Preparation Seven days after transplantation, the PLN of the leg that had been injected was removed. The cells were suspended in RPMI 1640 medium (Nissui Pharmaceutical Co., Ltd., Japan) supplemented with 10 % fetal calf serum, benzylpenicillin (200 u/ml), kanamycin (60^g/ml), L-glutamine (2 him), and 2-mercaptoethanol (5 x 10~5 m). In some experiments, PLNcells were treated with anti-Thy-1.2 (First Chemicals Co., Ltd., Japan) for 45 minutes at 4°C, washed, and treated with guinea pig complement diluted 1 : 10 (Wako Pure Chemical Industries, Ltd., Japan) for 45 minutes at 37°C.
Response to Exogenous IL-2 PLNcells (2 x 105) were cultured with or without mouse recombinant IL-2 (6 u, Nakarai Chemicals, Ltd., Japan) for 24 hours in a 96-well plate. During the final 6 hours of culture, 0.5^Ci of [3H]-thymidine ([3H]TdR; New England Nuclear Corp., U.S.A.) was added to each well and the incorporation of the label into the cultured cells was measured.
Preparation of Culture Supernatant Containing IL-2 and Macrophage Activating Factor (MAF)
The PLN cells (2 x lO6/ml) as responder cells were cultured with BALB/c spleen cells (2 x lO6/ml) that had been treated with 50^g/ml mitomycin C (Kyowa Hakko Kogyo Co., Ltd., Japan) as stimulator cells. After incubation for 24 hours, the culture supernatant of this mixed lymphocyte reaction was 
Statistical Analysis
Data were analyzed by Student's t-test.
Results
When spleen cells of BALB/c (H-2d) mice were injected, the total number of cells recovered 7 1 677 days later from the PLN of the C57BL/6 (H-2b) mice treated with saline was 6-fold the number recovered from untreated normal mice. Whenrecipients were treated with NKT-01,the number of cells was greater than in these saline-treated controls. WhenCyAwas used instead of NKT-01, the number of cells was slightly less than in the saline-treated controls ( Table 1) .
The proliferation of the PLNcells recovered in the presence of exogenous IL-2 was measured to evaluate their immunological functions (Table 2 ). In untreated normal mice, the cells had a little response to IL-2. However, cells from saline-treated control mice developed the response and proliferated in the presence of IL-2. Whenrecipients were treated, this proliferation was inhibited by 73 % compared to the saline-treated controls with NKT-01 and by 51 % with CyA.
Wenext studied the effects of NKT-01or CyA on the production of IL-2 and MAFby the PLN cells in the MLRbetween the cells and allogeneic spleen cells treated with mitomycin C. In culture supernatants of the PLNcells only, i.e. without stimulator cells, neither IL-2 nor
MAFwere detected (data not shown). NKT-01 enhanced IL-2 production by 27 %compared to the saline-treated controls, and CyAsuppressed it by 19% (Table 3) . MAFproduction in the MLRwas suppressed by both NKT-01 and CyA (Table 4) , with the inhibition caused by NKT-01 being higher than that of CyA. The production of MAFwas abolished by treatment of the PLN cells with anti-Thy-1.2 and complement (Table 5) , which showed that the production of MAFin our system was mediated by T-cells.
NKT-01 was also tested for effects on the PLNcells were obtained from C57BL/6 mice treated as described in the footnote to Table 1 and cultured for 24 hours with or without mouse recombinant IL-2. In untreated normal mice, cpm in culture without IL-2 was 155±27, and cpm with 30u/ml IL-2 was 419±56. Each value is the mean cpm from triplicate counts. a PLNcells were obtained from C57BL/6 mice treated as described in the footnote to Table 1 and cultured for 24 hours with BALB/c spleen cells that had been treated with mitomycin C. The IL-2 activity of the supernatant against the IL-2-dependent cell line CTLL-2 was assayed.
Each value is the mean cpm from triplicate counts.
b P<0.01. a PLNcells were obtained from C57BL/6 mice treated as described in the footnote to Table 1 and cultured for 24 hours with BALB/cspleen cells that had been treated with mitomycin C.
The MAF activity of the supernatant was assayed in terms of the cytostatic activity of macrophages against mouse leukemia L5178Y cells (E:T=2:1). The counts per minute of L5178Y cells were 23,414±802 without macrophages. Each value is the mean cpm from triplicate counts. days, and then rapidly regressed as the immunological rejection mechanism began to act (Fig. 1) . NKT-01delayed the rejection of tumor allografts. Whenthe daily dose of NKT-01was 3.13 mg/kg, rejection started on day 12, 6 days after the last injection. The changes in MAFactivity in the supernatant of the MLTRresembled those for footpad thickness (Fig. 2) . In saline-treated control mice, MAFproduction started on day 4 after transplantation, with the peak of the activity at day 6, inhibited MAFproduction during its administration. In mice treated with NKT-01, MAFproduction started on day ll (5 days after the last injection), the day before the start of the rejection of allogeneic tumors.
Discussion
Wefound someimmunosuppressivemodes of NKT-01using PLNcells from mice that were inoculated in the footpad with allogeneic cells.
First, NKT-01 significantly inhibited the response to exogenous IL-2 by the PLNcells, but IL-2 production in the MLRbetween the cells and allogeneic spleen cells was enhanced in mice treated with NKT-01. Both response and production were inhibited by CyA. NKT-01
had a different mechanism from CyA. NKT-01 enhanced IL-2 production, so the inhibition of the response to IL-2 was not caused by decreased IL-2 production. We speculate that NKT-01 decreases the numberof IL-2 receptors, or else imoairs the function of the IL-2 receotor directly, so that the T-cells that participate in allograft rejection are not activated. Second, NKT-01 suppressed MAFproduction by the PLN cells in the MLR. In the experiment with allogeneic tumor cells used as allografts, there seemed to be a close relationship between the suppression of MAFproduction and the inhibition of allograft rejection. Dickneite et al.5) observed that NKT-01suppresses the secretion of both hydrolytic enzymes and IL-1 and also suppresses the chemiluminescence reaction in monocytes/macrophages during rat skin transplantation. However, Masuda et alJ^have reported that immunosuppressive NKT-01does not reduce functions of zymosanactivated macrophages such as the release of lysosomal enzymes and the production of superoxide anions, so the effects of NKT-01on the functions of macrophages are uncertain. Wecould not assay the functions of macrophages in the PLNbecause there were too few. The suppression of MAFproduction by NKT-01would inhibit macrophage activation, and macrophages act in allograft rejection10"1^. Thus, the suppression of MAFproduction by NKT-01 participates in the suppression of allograft rejection.
NKT-01is a new kind of immunosuppressive drug. It affected some functions mediated by T-cells, so that it inhibited the response to IL-2 and suppressed MAFproduction. Also, NKT-01 increased the numbers of cells recovered from the PLN7 days after inoculation. The distribution of lymphocyte subsets in the PLN may be changed greatly by NKT-01. More study is needed to understand the mechanism of NKT-01in the response of hosts to allografts.
